Cargando…

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

AIM: To assess the efficacy and safety of fasiglifam 25 and 50 mg in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. METHODS: This phase III, double-blind, placebo-controlled, multicentre study included 192 patients randomized to once-daily treatment with fasigli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaku, K, Enya, K, Nakaya, R, Ohira, T, Matsuno, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676912/ https://www.ncbi.nlm.nih.gov/pubmed/25787200 http://dx.doi.org/10.1111/dom.12467

Ejemplares similares

Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 Diabetes
por: Kaku, Kohei, et al.
Publicado: (2013)

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1
por: Yabuki, Chiori, et al.
Publicado: (2013)

Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent Manner
por: Kim, MinJeong, et al.
Publicado: (2018)

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury
por: Wolenski, Francis S., et al.
Publicado: (2017)

Fasiglifam (TAK‐875) has dual potentiating mechanisms via Gαq‐GPR40/FFAR1 signaling branches on glucose‐dependent insulin secretion
por: Sakuma, Kensuke, et al.
Publicado: (2016)

Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus
por: Naik, H, et al.
Publicado: (2013)

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
por: Seino, Yutaka, et al.
Publicado: (2021)

A high molar activity (18)F-labeled TAK-875 derivative for PET imaging of pancreatic β-cells
por: Dornan, Mark H., et al.
Publicado: (2018)

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
por: Kadowaki, Takashi, et al.
Publicado: (2021)

Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy
por: Kaku, Kohei, et al.
Publicado: (2014)

TAK-875 Mitigates β-Cell Lipotoxicity-Induced Metaflammation Damage through Inhibiting the TLR4-NF-κB Pathway
por: Chen, Xide, et al.
Publicado: (2019)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury
por: Longo, Diane M, et al.
Publicado: (2019)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
por: Marcinak, John, et al.
Publicado: (2018)

TAK1ng control: TAK1 restrains NLRP3 activation
por: Mangan, Matthew Stephen, et al.
Publicado: (2018)

Efficacy and safety of the G protein‐coupled receptor 119 agonist DS‐8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo‐controlled study
por: Terauchi, Yasuo, et al.
Publicado: (2018)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function
por: Mayer, Michael, et al.
Publicado: (2014)

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
por: Ratner, R E, et al.
Publicado: (2010)

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
por: Gantz, Ira, et al.
Publicado: (2017)

Correction to Lancet Psychiatry 2020; 7: 875–82
Publicado: (2020)

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018)

Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

875 Prospective Monitoring of Indwelling Urinary Catheters in Hospitalized Patients
por: Yoon, Bona, et al.
Publicado: (2014)

Author Correction: Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement
por: Suzuki, Atsushi, et al.
Publicado: (2021)

Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo‐controlled trial
por: Kaku, Kohei, et al.
Publicado: (2019)

CD40L Priming of Platelets via NF‐κB Activation is CD40‐ and TAK1‐Dependent
por: Kojok, Kevin, et al.
Publicado: (2018)

Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma
por: Molfino, Nestor A, et al.
Publicado: (2016)

Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist
por: Fujimoto, Tatsuhiko, et al.
Publicado: (2022)

875. Sex Differences in Academic Achievement and Faculty Rank in Academic Infectious Diseases
por: Manne-Goehler, Jennifer, et al.
Publicado: (2018)

TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation
por: Malireddi, R.K. Subbarao, et al.
Publicado: (2018)

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Nauck, Michael A., et al.
Publicado: (2015)

A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects
por: Esfandiari, Ehsanollah, et al.
Publicado: (2021)

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study
por: Sanacora, Gerard, et al.
Publicado: (2017)

Analysis of inadequate cervical smears using Shewhart control charts
por: Harrison, Wayne N, et al.
Publicado: (2004)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial
por: Täubel, Jörg, et al.
Publicado: (2016)

Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin
por: Kawamori, Ryuzo, et al.
Publicado: (2015)

875. Pseudo-outbreak of Clostridioides (Clostridium) difficile amongst post-operative Oncology Patients
por: Kagedan, Daniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7hrboli6fe6ltv13cqng6ir50u